Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717592 | 0.82 | MAPK14 (0.50) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4638304 | 0.81 | SMN1; SMN2 (0.44) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4718758 | 0.80 | MAPK14 (0.54) | MAPK14FLT3RAB9AMEN1KMT2A | |
| SCHEMBL4881650 | 0.80 | MEN1 (0.53) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4716331 | 0.80 | MEN1 (0.60) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4718593 | 0.80 | KMT2A (0.51) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4716593 | 0.78 | MEN1 (0.52) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL4716046 | 0.78 | MAPK14 (0.55) | MAPK14MAPK13MAPT | |
| SCHEMBL4714451 | 0.77 | MAPK14 (0.62) | MAPK14MAPK13FLT3RAB9AMEN1 | |
| SCHEMBL5252966 | 0.75 | MAPK14 (0.47) | MAPK14MAPK13FLT3RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | MAPK14 2983/4885MAPK13 2414/4885FLT3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.